A UCLA study has outlined a new framework that researchers say would improve predictive power of genetics to determine how well a patient would respond to commonly prescribed medications as well as the severity of any side effects.
Researchers from the University of Chicago recently developed a new approach for identifying new cellular RNA targets of snoRNAs. They uncovered thousands of previously unknown targets for snoRNAs in human cells and mouse brain tissues, including many that serve functions other than guiding rRNA modifications.
Researchers at Case Western Reserve University have identified a new target to treat atherosclerosis, a condition where plaque clogs arteries and causes major cardiac issues, including stroke and heart attack.
A new method developed by University of Michigan researchers creates images that are worth many gigabytes of data, which could revolutionize the way biologists study gene expression.
Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way that ovarian cancer tumors manipulate their environment to resist immunotherapy and identified a drug target that could overcome that resistance. The study, published in the October 30 online issue of Cell used a cutting-edge spatial genomics technology and preclinical animal models, with tumor specimens from ovarian cancer patients further validating the findings. They found that ovarian cancer cells produce a molecule called Interleukin-4 (IL-4), which is typically associated with asthma and the skin condition eczema, also known as atopic dermatitis. The study went on to find that the cancer cells used IL-4 to create a protective environment that kept away killer immune cells, making the tumors resistant to immunotherapy. A drug, dupilumab, which blocks IL-4’s activity, has been approved by the Food and Drug Administration (FDA) and is already used to treat asthma and eczema. This new study suggests dupi
It acts as a sort of molecular fumigator to battle phages and plasmids.
A recent study published by Dr. Jordan Verplank, Assistant Professor in the Department of Anatomy, Physiology, and Genetics at the Uniformed Services University of the Health Sciences (USU), and a team of scientists from USU, State University of Buffalo (New York), and Cyclerion Therapeutics, has identified a promising approach for treating hereditary peripheral neuropathies, specifically Charcot Marie Tooth disease types 1A (CMT1A) and 1B (CMT1B). By focusing on increasing levels of cyclic guanosine monophosphate (cGMP) – a signaling molecule involved in various biological processes – the study has shown potential improvements in myelination, nerve conduction, and motor coordination in mouse models affected by these conditions. The findings were published in Cellular and Molecular Life Sciences on October 14, 2024.
Researchers at Rutgers University-New Brunswick, along with international collaborators, have introduced a novel method for identifying the crucial set of gut microbes commonly found in humans and essential for health.
Researchers with The Ohio State University Comprehensive Cancer Center – Arthur G. James and Richard J. Solove Research Institute are trying to improve outcomes for patients with a deadly form of brain cancer known as glioblastoma.
A research team at the National Cancer Institute-designated Montefiore Einstein Comprehensive Cancer Center (MECCC) has discovered a natural immune mechanism in mice that stops escaped cancer cells from developing into tumors elsewhere in the body. The findings were published today in the journal Cell.
TAMPA, Fla. - A new study published in Cell Press reveals critical insights into the role of gamma-delta T cells across 33 cancer types, shedding light on their potential as clinical biomarkers and therapeutic targets in cancer treatment. Led by a team of researchers at Moffitt Cancer Center, this comprehensive analysis represents a significant advancement in the understanding of these unique immune cells and their implications for patient outcomes in cancer therapy.
In two new papers, both published in Cell Reports Medicine, researchers from the University of Michigan Rogel Cancer Center describe the mechanisms of how alterations in the CDK12 gene drive prostate cancer development and report on a promising degrader that targets CDK12 and a related gene to destroy tumors.
A new pathology tool created at Yale harnesses barcode technology and shows potential for use in cancer diagnoses. The technology, Patho-DBiT (pathology-compatible deterministic barcoding in tissue), was discussed in a new study that published Sept. 30 in the journal Cell. Co-corresponding author Dr. Mina Xu, a Yale Cancer Center (YCC) member, professor of pathology at Yale School of Medicine (YSM), and the YSM director of hematopathology, shared her enthusiasm for the new tool.
UC San Diego researchers discover two distinct molecular subtypes of Crohn’s disease using patient-derived organoids, opening the door to personalized treatment for the chronic inflammatory bowel disease.
New research from Memorial Sloan Kettering Cancer Center (MSK) uses saturation genome editing to better understanding of the RAD51C gene, which has been linked to higher risks of breast and ovarian cancer; sheds new light on brain metastasis; and finds a commercially available contrast dye could help surgeons better separate cancer from healthy tissue.
The new study, led by researchers in the Saphire Lab at LJI, reveals the inner workings of the Ebola virus nucleocapsid. LA JOLLA, CA—At this moment, the world has few tools to combat deadly filoviruses, such as Ebola and Marburg viruses. The only approved vaccine and antibody treatments protect against just one filovirus species.
Researchers have for the first time identified degeneration-associated “molecular markers” – observable changes in cells and their gene-regulating networks – that are shared by several forms of dementia that affect different regions of the brain.
Violent blows or jolts to the head can cause traumatic brain injury (TBI), and there are currently about five million people in the U.S. living with chronic neurodegeneration and related impairments due to TBI.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
